Di Federico A.; Andrini E.; Sisi M.; Nuvola G.; Lamberti G.; Lenzi B.; Nobili E.; Gelsomino F.; Ardizzoni A., Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution, «ANTI-CANCER DRUGS», 2021, 32, pp. 755 - 757 [articolo]Open Access
Ricci C.; Lamberti G.; Ingaldi C.; Mosconi C.; Pagano N.; Alberici L.; Ambrosini V.; Manuzzi L.; Monari F.; Malvi D.; Rosini F.; Minni F.; Campana D.; Casadei R., Treatment of advanced gastro‐entero‐pancreatic neuro‐ endocrine tumors: A systematic review and network meta‐analysis of phase iii randomized controlled trials, «CANCERS», 2021, 13, Article number: 358, pp. 1 - 14 [articolo]Open Access
Spada F.; Campana D.; Lamberti G.; Laudicella R.; Dellamano R.; Dellamano L.; Leeuwenkamp O.; Baldari S., [177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective, «EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING», 2021, 49, pp. 2037 - 2048 [articolo]Open Access
Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F., Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience, «EXPERT OPINION ON BIOLOGICAL THERAPY», 2020, 20, pp. 1047 - 1059 [articolo]
Ricciuti B.; Naqash A.R.; Naidoo J.; Sehgal K.; Miller A.; Kehl K.; Venkatraman D.; Sands J.; Lamberti G.; Recondo G.; Zhang J.; Macherla S.; Baig S.; Walker P.; Rangachari D.; Gainor J.F.; Costa D.B.; Rizvi N.; Sholl L.M.; Nishino M.; Henick B.; Farago A.F.; Awad M.M., Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC, «JTO CLINICAL AND RESEARCH REPORTS», 2020, 1, Article number: 100074, pp. 1 - 9 [articolo]Open Access
Gelsomino F.; Lamberti G.; Tiseo M.; Rocco D.; Pasello G.; Cecere F.L.; Chella A.; Grilli G.; Mandruzzato M.; Tognetto M.; Garassino M.C.; Macerelli M.; Novello S.; Roila F.; Colantonio I.; Grossi F.; Fiorentino M.; Ardizzoni A., Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial), «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2020, 12, pp. 1 - 6 [articolo]Open Access
Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A., Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2020, 156, Article number: 103119, pp. 1 - 18 [articolo]
Brighi N.; Panzuto F.; Modica R.; Gelsomino F.; Albertelli M.; Pusceddu S.; Massironi S.; Lamberti G.; Rinzivillo M.; Faggiano A.; Spallanzani A.; Ferone D.; Prinzi N.; Rossi R.E.; Annibale B.; Colao A.M.; Campana D., Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study, «THE ONCOLOGIST», 2020, 25, pp. 259 - 265 [articolo]
Lamberti G.; Spurr L.F.; Li Y.; Ricciuti B.; Recondo G.; Umeton R.; Nishino M.; Sholl L.M.; Meyerson M.L.; Cherniack A.D.; Awad M.M., Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer, «ANNALS OF ONCOLOGY», 2020, 31, pp. 807 - 814 [articolo]
Parisi C.; Lamberti G.; Zompatori M.; Gelsomino F.; Salvagni S.; Sperandi F.; Ardizzoni A., Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer, «JOURNAL FOR IMMUNOTHERAPY OF CANCER», 2020, 8, pp. 1 - 3 [articolo]Open Access
Panzuto F.; Massironi S.; Partelli S.; Campana D.; Rinzivillo M.; Invernizzi P.; Andreasi V.; Lamberti G.; Falconi M., Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management, «SURGICAL ONCOLOGY», 2020, 35, pp. 141 - 148 [articolo]
Abu-Sbeih H.; Faleck D.M.; Ricciuti B.; Mendelsohn R.B.; Naqash A.R.; Cohen J.V.; Sellers M.C.; Balaji A.; Ben-Betzalel G.; Hajir I.; Zhang J.; Awad M.M.; Leonardi G.C.; Johnson D.B.; Pinato D.J.; Owen D.H.; Weiss S.A.; Lamberti G.; Lythgoe M.P.; Manuzzi L.; Arnold C.; Qiao W.; Naidoo J.; Markel G.; Powell N.; Yeung S.-C.J.; Sharon E.; Dougan M.; Wang Y., Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease, «JOURNAL OF CLINICAL ONCOLOGY», 2020, 38, pp. 576 - 583 [articolo]Open Access
Tateo V.; Manuzzi L.; De Giglio A.; Parisi C.; Lamberti G.; Campana D.; Pantaleo M.A., Immunobiology of thymic epithelial tumors: Implications for immunotherapy with immune checkpoint inhibitors, «INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES», 2020, 21, Article number: 9056, pp. 1 - 16 [articolo]Open Access
Ricciuti B.; Recondo G.; Spurr L.F.; Li Y.Y.; Lamberti G.; Venkatraman D.; Umeton R.; Cherniack A.D.; Nishino M.; Sholl L.M.; Shapiro G.I.; Awad M.M.; Cheng M.L., Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer, «CLINICAL CANCER RESEARCH», 2020, 26, pp. 4135 - 4142 [articolo]
Maggio I.; Manuzzi L.; Lamberti G.; Ricci A.D.; Tober N.; Campana D., Landscape and future perspectives of immunotherapy in neuroendocrine neoplasia, «CANCERS», 2020, 12, pp. 832 - 856 [articolo]Open Access
